Current and historical daily PE Ratio for Cosmo Pharmaceuticals NV (
CHIX:COPNz
) from 2016 to May 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Cosmo Pharmaceuticals NV stock (CHIX:COPNz) PE ratio as of May 24 2024 is 109.16.
More Details
Cosmo Pharmaceuticals NV (CHIX:COPNz) PE Ratio (TTM) Chart
Cosmo Pharmaceuticals NV (CHIX:COPNz) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1256
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Cosmo Pharmaceuticals NV PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-24 | 111.0 | 2024-03-19 | 101.1 |
| 2024-05-23 | 111.0 | 2024-03-18 | 100.9 |
| 2024-05-22 | 111.3 | 2024-03-15 | 104.6 |
| 2024-05-21 | 109.0 | 2024-03-14 | 102.7 |
| 2024-05-20 | 111.2 | 2024-03-13 | 102.6 |
| 2024-05-17 | 111.2 | 2024-03-12 | 102.0 |
| 2024-05-16 | 112.2 | 2024-03-11 | 103.5 |
| 2024-05-15 | 112.1 | 2024-03-08 | 104.4 |
| 2024-05-14 | 109.8 | 2024-03-07 | 104.1 |
| 2024-05-13 | 108.5 | 2024-03-06 | 102.4 |
| 2024-05-10 | 107.6 | 2024-03-05 | 102.1 |
| 2024-05-09 | 108.5 | 2024-03-04 | 102.9 |
| 2024-05-08 | 108.5 | 2024-03-01 | 102.3 |
| 2024-05-07 | 109.5 | 2024-02-29 | 100.6 |
| 2024-05-03 | 108.8 | 2024-02-28 | 100.3 |
| 2024-05-02 | 109.0 | 2024-02-27 | 100.8 |
| 2024-05-01 | 111.8 | 2024-02-26 | 101.7 |
| 2024-04-30 | 111.8 | 2024-02-23 | 100.2 |
| 2024-04-29 | 109.8 | 2024-02-22 | 99.5 |
| 2024-04-26 | 109.6 | 2024-02-21 | 98.9 |
| 2024-04-25 | 110.5 | 2024-02-20 | 98.5 |
| 2024-04-24 | 115.0 | 2024-02-19 | 100.2 |
| 2024-04-23 | 112.7 | 2024-02-16 | 98.9 |
| 2024-04-22 | 112.3 | 2024-02-15 | 98.8 |
| 2024-04-19 | 108.1 | 2024-02-14 | 98.8 |
| 2024-04-18 | 108.4 | 2024-02-13 | 98.6 |
| 2024-04-17 | 107.3 | 2024-02-12 | 97.7 |
| 2024-04-16 | 107.3 | 2024-02-09 | 97.0 |
| 2024-04-15 | 106.6 | 2024-02-08 | 96.3 |
| 2024-04-12 | 105.5 | 2024-02-07 | 94.3 |
| 2024-04-11 | 105.5 | 2024-02-06 | 93.7 |
| 2024-04-10 | 106.9 | 2024-02-05 | 93.4 |
| 2024-04-09 | 108.8 | 2024-02-02 | 92.8 |
| 2024-04-08 | 107.8 | 2024-02-01 | 95.2 |
| 2024-04-05 | 106.6 | 2024-01-31 | 97.6 |
| 2024-04-04 | 106.1 | 2024-01-30 | 96.8 |
| 2024-04-03 | 104.1 | 2024-01-29 | 97.3 |
| 2024-04-02 | 105.3 | 2024-01-26 | 95.0 |
| 2024-03-28 | 108.1 | 2024-01-25 | 94.8 |
| 2024-03-27 | 106.1 | 2024-01-24 | 95.1 |
| 2024-03-26 | 99.4 | 2024-01-23 | 94.3 |
| 2024-03-25 | 101.8 | 2024-01-22 | 93.0 |
| 2024-03-22 | 101.1 | 2024-01-19 | 92.5 |
| 2024-03-21 | 97.3 | 2024-01-18 | 92.1 |
| 2024-03-20 | 102.6 | 2024-01-17 | 91.9 |
Cosmo Pharmaceuticals NV (CHIX:COPNz) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Cosmo Pharmaceuticals NV
ISIN : NL0011832936
Share Class Description:
CHIX:COPNz: Registered SharesDescription
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers